Antheia utilizes synthetic biology to manufacture biosynthetic Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) for essential medicines, enhancing the reliability and efficiency of pharmaceutical supply chains. This approach mitigates the risks of drug shortages caused by unpredictable agricultural sources and environmental factors.
Funding
$12M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
USFounders
Product
Problem
The pharmaceutical industry relies on traditional methods, like agriculture and chemical synthesis, to produce key starting materials (KSMs) and active pharmaceutical ingredients (APIs) for essential medicines. These methods are often inefficient, inflexible, and susceptible to climate events, leading to unpredictable yields and drug shortages. Many API manufacturers are located outside the U.S., creating supply chain vulnerabilities.
Solution
Antheia uses synthetic biology to manufacture biosynthetic KSMs and APIs for essential medicines, offering a more efficient, agile, and sustainable alternative to traditional methods. The company's biomanufacturing platform leverages engineered microorganisms to produce complex pharmaceutical ingredients at scale, reducing reliance on fragile agricultural sources and mitigating supply chain risks. By engineering biosynthesis pathways in yeast, Antheia enables resilient and scalable pharmaceutical supply chains, domestic and rapid-response manufacturing, and more equitable channels of distribution. This approach reduces timelines from years to weeks, lowers the environmental footprint, and provides predictable and consistent yields.
Target Audience
Antheia's primary customers are pharmaceutical companies and healthcare providers seeking a reliable and sustainable supply of essential medicine ingredients, as well as organizations looking to mitigate drug shortages and improve supply chain resilience.
Features
- Biomanufacturing platform using engineered microorganisms for efficient production of complex APIs and KSMs
- Production of thebaine, a key ingredient for pain management and addiction management medications
- Capability to produce over 70 other ingredients, including scopolamine for anti-nausea medications
- Commercial-scale fermentation runs producing 116,000 liters of thebaine in approximately five days
- Partnership with biomanufacturers to scale production techniques
- Technology to engineer yeast with genes from multiple species to produce specialty chemicals
- Capability to produce ingredients for drugs facing significant shortages